|
|
Post by barnstormer on May 20, 2020 8:48:57 GMT -5
BABA That NVAX Magic is a little low today. Stan's offering is killing the Mojo. These BIO CEOs think dilution is the only solution.
|
|
|
|
Post by barnstormer on May 20, 2020 7:42:18 GMT -5
Any insights in how they are handling the Q&A?
|
|
|
|
Post by barnstormer on Apr 21, 2020 14:00:01 GMT -5
Let’s start a list of questions for the annual shareholder meeting..... 1.....Mike, “how soon before you need to use those shares?” We should go back through all of Mike's presentations and do a little fact checking and ask what happened to Afrezza in Mexico and Canada? What's the status of the Cipla studies? What are the prescritption numbers out of Brazil? |
|
|
|
Post by barnstormer on Apr 21, 2020 8:10:27 GMT -5
You guys really think bankruptcy is still on the table? Ok... On that note, my comment would be that you can't believe that bankruptcy is a far fetched idea? There are 16 references to the fact that it is doubtful that the company can continue as a going concern without additional funding in the latest 10K (including a Statement from their independent auditor - Deloitte & Touche). Sports, I am not trying to argue with you, I just want to point out to those that may have not had real hands on experience with a start-up (yes, this is still a start-up), that available shares are the lifeblood until profitability. Anything can happen. We still have no idea how long the Coronavirus Crisis will last among other things. While I don't think retail investors can prevent these from becoming authorized, I wanted to point out to long investors that running out of shares to issue will cripple an investment. The language you are talking about can be seen in the 10Ks of many publicly traded companies. It is almost boilerplate added by the legal teams to protect the officers in an unforseen event. I don't make investing decisions or lose sleep over those types of clauses in a 10K. |
|
|
|
Post by barnstormer on Apr 12, 2020 23:11:22 GMT -5
Seriously Casper. You said "I don't see why you're saying MNKD has poor management. Sales are growing. Brazil is growing. UTHR is in BED with MNKD in a big way. The company is strong. And ALL of this has been done with NO MONEY. Hell the CFO has done a magnificent job and I guess you feel he shouldn't get a bonus.
Sales should have been over 1.000 scrips by now. Brazil? You have no idea how much they are contributing. Mike isdn't posting anything. UTHR? There is no gurantee that is going to pan out. The reason "all of this has been done with NO MONEY" is because the CEO can't get a deal done with a partner bringing in big money. Thanks for making my point. GL2U.
|
|
|
|
Post by barnstormer on Apr 12, 2020 7:36:12 GMT -5
Casper, what I/we expect is a lot more transparency from management. You obviously support them. Many of us do not. You are right, there are 3 drug companies that have a lot to lose if Afrezza reaches success anywhere near what Al Mann thought it would. A strong experienced CEO (not a learn on the job guy) would be doing a lot more to defend the share price. That is after all one of the responsibilities of the leader of a public company. The challenge Afrezza has to be a disrupter isn't the first and won't be the last. This management team just doesn't have what it takes to deliver so the share price continues to suffer. The December raise was a gaffe no matter how you try to spin it. The deals Mike has with BIOMM, Cipla, and Immix have no upfront cash. If a CEO can't sell potential partners/companies with cash than this proves he is a horrible negotiator or just picks poor partners. He has said for two years he is working on deals with Mexico and Canada. Where are they? He tossed one away in UAE. I hope sooner rather than later the intsitutional owners who really have the power to make changes at the top sober up and say enough is enough. Otherwise we are at the mercy of a poor management team whose track record will continue to disappoint. And by the way. Don't be smug and tell us we should sell our shares and invest them somewhere else. Many of us longs didn't sell because Mike assured us "he never fails", "we are going to be just fine", "you'll thank me later". And you wonder why we don't think he is entitled to a raise? Let alone continued employment. I have to laugh.
|
|
|
|
Post by barnstormer on Apr 8, 2020 23:47:02 GMT -5
Once again MNKD is working with an unknown company with unknown funds to research a potential CV 19 drug? IMMIX is even more speculative than RLS. I am trying to find some relivance and rationalization for this partnership. When one of your main studies deals with dogs? I love dogs, but Mike needs to help us understand WTF is going on. 1 dog, 2 humans? How did the humans fare? Were they able to go back to their normal routines? Who's financing this Mike? My point is IMMIX has no experience in Corona Virus. Where is the value in this relationship? Are we that desperate to throw this on the wall and see if it sticks? Immix Observes Complete Response in Late-Stage Canine Cancer Patient and Doses First Two Patients in Human Phase 1b/2a Study by Ryan | Aug 6, 2018 | Press Releases | immixbio.com/2018/08/06/immix-observes-complete-response-in-late-stage-canine-cancer-patient-and-doses-first-two-patients-in-human-phase-1b2a-study/LOS ANGELES, Calif. (Aug. 6, 2018, 7:30 AM EST) – Immix Biopharma Inc. announced today that it has observed the complete response of an advanced, spontaneous malignancy in a 10-year-old companion dog after the administration of a single cycle of Imx-110. The dog showed a complete resolution of all clinical signs of disease several days after dosing, with immediate improvement in appetite and energy levels. The patient experienced no decrease in white blood cells – a reaction typically seen with standard treatment doxorubicin – or any other adverse effects. Less than a week after treatment, he returned to his usual activities, according to his owner. While this observed response was impressive, the company cautions that it is still a sample size of 1 and more studies are needed on larger canine patient cohorts. |
|
|
|
Post by barnstormer on Apr 8, 2020 9:06:18 GMT -5
|
|
|
|
Post by barnstormer on Apr 5, 2020 11:26:21 GMT -5
The alternative UVLUA is the transparency Mike has promised since taking the CEO position. Share price can be directly affected by information coming from the CEO. A couple of months ago we were at $1.50 thinking the warrants would be taken out as the price climbed. Mike sends a PR about a deal he made with an unknown private company working on a CV 19 drug. SP jumped over $.10, not much but it would get us over a buck now. He stated he was overhauling the pipeline. No followup on what that means. He will probably say he did a great job of raising the SP after the reverse split shows yet another fake value. He hides the revenue coming from the Brazil market while it may not be much it is still a revenue stream. If he continues his business as usual ways we will be forced to to a reverse split to stay in NASDAQ compliance. There is really no reason other than his MIA approach that we shouldn' be back into the $1.50 range safely out of RS territory. Good CEOs defend share price. Mike ignores it. As investors we need to graphically show Mike and the board that is is unacceptable.
|
|
|
|
Post by barnstormer on Apr 5, 2020 8:30:24 GMT -5
We need to do a petition against the Reverse Split that we all suspect will happen if Mike can't get share price back over a dollar. |
|
|
|
Post by barnstormer on Apr 2, 2020 9:45:47 GMT -5
Mike has only one deal where he scored cash from a partner and that was with UTHR (Al's friend Martine). Immix Biopharma, his new partner is a private company with no money and no experience with anything CV 19 related yet they will have to spend big money to devlope a drug in a highly speculative and now crowded CV-19 market. The offering is the only hope either of them have right now for R&D. The share price is in deep NASDAQ non compliance territory now with another possible RS on our horizon. An RS before the shares are granted would be a fiasco and an RS after the shares are granted and a quick short raid would also be a fiasco. Mike got us in this mess and it's time for him to show us his way out of this mess or give us his key to the executive wash room.
|
|
|
|
Post by barnstormer on Apr 1, 2020 8:35:12 GMT -5
The only good thing about the CV lockdown for Mike is he won't have to face angry investors like me and others at the ASM. Saved by the bug.
|
|
|
|
Post by barnstormer on Mar 17, 2020 17:15:38 GMT -5
Well if nothing else Mike has found a way to change the narrative away from his current failings of Afrezza to something else. Another spec play with no cash. It's like RLS 2.0. I have often wondered why if TS is so incredible (and I think it is) why hasn't management pursued more drug candidates where TS delivers something specifically beneficial for lungs ailments with a built in cough suppressant. What MNKD needs is a partner with cash, a sales force and a good drug. This euphoria will be short lived unless there is cash to get it to market.
|
|
|
|
Post by barnstormer on Mar 3, 2020 9:12:43 GMT -5
Sometimes when you really don't have strong numbers to justify your existence you just make them up. Thus the 22%. As they say figures don't lie, but liars can figure. He will ask for shares for sure. He told us in the ASM 2 years ago he wanted to keep a stockpile of shares on hand to take advantages of "opportunities like acquisitions". I think I accidentally laughed out loud. Interesting read. www.mmm-online.com/home/channel/features/mannkind-version-2-0-ceo-michael-castagna-faces-his-biggest-test-yet-with-afrezza-reboot/ “We know that the company will be here for the long run and we can control our own destiny,” Castagna says, crediting director, corporate communications Naomi Bandison-Johnson as the driving force behind the new brand. MannKind has not hired a replacement for chief marketing officer Garrett Ingram, who left the company in June. We’ll be one of the mainstays. We did an assessment and identified three to five new opportunities we think we can win in and start to move forward. We’re just getting started. Michael Castagna, MannKind |
|
|
|
Post by barnstormer on Mar 1, 2020 1:14:55 GMT -5
Novavax has a platform that uses recombinant nanoparticle vaccine technology that can respond to known and emerging infectious diseases. In some ways they are like the TS of vaccines. Dangerous? I think the only thing dangerous about NVAX is their CEO (sound familiar). The reason they are quick to get in the COVID 19 fray is because they have a lot of experience with similar pathogens. Right now they are doing more to save my biotech portfolio that MNKD. They have been given a $27.50 PT by several analysts based on the expected FDA approval of NanoFlu which is more important than COVID 19. MNKD was in the $50 range when I first bought in and look at it now. I lived through Stan Erk's (NVAX CEO) 1:20 RS, averaged down and am gleefully up big now. Long term I think NVAX's RSV drug will get a second chance at FDA approval. After all the Bill & Melinda Gates Foundation invested $96,000,000. Like MNKD they are survivors and in a business that doesn't rely on endos to prescribe their drugs. I am feeling pretty good with my NVAX investment. MN KD, not so much.
|
|
